Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study

REFERENCES

1. 1.↵
   1. Wolfe F,
   2. Michaud K

   . The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612–21.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Gabriel SE,
   2. Crowson CS,
   3. O’Fallon WM

   . Comorbidity in arthritis. J Rheumatol 1999;26:2475–9.

   OpenUrlPubMed
3. 3.↵
   1. Radner H,
   2. Yoshida K,
   3. Smolen JS,
   4. Solomon DH

   . Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatol 2014;10:252–6.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Toms TE,
   2. Panoulas VF,
   3. Douglas KM,
   4. Griffiths H,
   5. Sattar N,
   6. Smith JP,
   7. et al.

   Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010;69:683–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Yelin E,
   2. Tonner C,
   3. Kim SC,
   4. Katz JN,
   5. Ayanian JZ,
   6. Brookhart MA,
   7. et al.

   Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. Arthritis Care Res 2014;66:980–9.

   OpenUrlCrossRef
6. 6.↵
   1. Radovits BJ,
   2. Fransen J,
   3. Eijsbouts A,
   4. van Riel PL,
   5. Laan RF

   . Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology 2009;48:906–10.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Tutuncu Z,
   2. Reed G,
   3. Kremer J,
   4. Kavanaugh A

   . Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006;65:1226–9.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Redelmeier DA,
   2. Tan SH,
   3. Booth GL

   . The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516–20.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Bologna C,
   2. Viu P,
   3. Jorgensen C,
   4. Sany J

   . Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996;35:453–7.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Fiehn C,
    2. Kessler S

    . [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months]. [Article in German] Z Rheumatol 2009;68:69–74.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Cui J,
    2. Stahl EA,
    3. Saevarsdottir S,
    4. Miceli C,
    5. Diogo D,
    6. Trynka G,
    7. et al.

    Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Ranganath VK,
    2. Maranian P,
    3. Elashoff DA,
    4. Woodworth T,
    5. Khanna D,
    6. Hahn T,
    7. et al.

    Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology 2013;52:1809–17.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Bijlsma JW,
    4. Breedveld FC,
    5. Boumpas D,
    6. Burmester G,
    7. et al;
    8. T2T Expert Committee

    . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Dougados M,
    2. Soubrier M,
    3. Antunez A,
    4. Balint P,
    5. Balsa A,
    6. Buch MH,
    7. et al.

    Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum dis 2014;73:62–8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Radner H,
    2. Yoshida K,
    3. Mjaavatten MD,
    4. Frits M,
    5. Lu B,
    6. Shadick N,
    7. et al.

    Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Paris: Annual European Congress of Rheumatology; 2014.
17. 17.↵
    1. Dougados M,
    2. Simon P,
    3. Braun J,
    4. Burgos-Vargas R,
    5. Maksymowych WP,
    6. Sieper J,
    7. et al.

    ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/ epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249–51.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Felson DT,
    2. Smolen JS,
    3. Wells G,
    4. Zhang B,
    5. van Tuyl LH,
    6. Funovits J,
    7. et al.

    American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Smolen JS,
    2. Landewé R,
    3. Breedveld FC,
    4. Buch M,
    5. Burmester G,
    6. Dougados M,
    7. et al.

    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Maradit-Kremers H,
    2. Nicola PJ,
    3. Crowson CS,
    4. Ballman KV,
    5. Gabriel SE

    . Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Crowson CS,
    2. Liao KP,
    3. Davis JM 3rd,
    4. Solomon DH,
    5. Matteson EL,
    6. Knutson KL,
    7. et al.

    Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013;166:622–8 e1.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Liao KP,
    2. Solomon DH

    . Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 2013;52:45–52.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Jamnitski A,
    2. Visman IM,
    3. Peters MJ,
    4. Dijkmans BA,
    5. Voskuyl AE,
    6. Nurmohamed MT

    . Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010;69:1929–33.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Tam LS,
    2. Tomlinson B,
    3. Chu TT,
    4. Li TK,
    5. Li EK

    . Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495–8.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Barnabe C,
    2. Martin BJ,
    3. Ghali WA

    . Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522–9.

    OpenUrlCrossRef
26. 26.↵
    1. Listing J,
    2. Gerhold K,
    3. Zink A

    . The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53–61.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Listing J,
    2. Strangfeld A,
    3. Kary S,
    4. Rau R,
    5. von Hinueber U,
    6. Stoyanova-Scholz M,
    7. et al.

    Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403–12.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Weinblatt M,
    2. Combe B,
    3. Covucci A,
    4. Aranda R,
    5. Becker JC,
    6. Keystone E

    . Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807–16.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Kremer JM,
    2. Dougados M,
    3. Emery P,
    4. Durez P,
    5. Sibilia J,
    6. Shergy W,
    7. et al.

    Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263–71.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Matteson EL,
    2. Bongartz T

    . Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2007;3:14–5.

    OpenUrlPubMed
31. 31.↵
    1. Putrik P,
    2. Ramiro S,
    3. Kvien TK,
    4. Sokka T,
    5. Pavlova M,
    6. Uhlig T,
    7. et al;
    8. Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’

    . Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198–206.

    OpenUrlAbstract/FREE Full Text